Q-omics provides the consensus-scored OR12D1 profile across patient tissues and cancer cell-line models. OR12D1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OR12D1 is differentially expressed in 1, with the highest sampling consensus in CHOL. Additionally, OR12D1 RNA expression shows 7,533 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight MESO, CHOL, and LIHC as cancer lineages where OR12D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR12D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR12D1 survival associations across molecular data types. OR12D1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR12D1 RNA expression–survival associations across cancer types. High OR12D1 expression shows unfavorable associations in MESO, COAD, LIHC, BLCA, UCEC and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OR12D1 RNA expression.
This table summarizes OR12D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for OR12D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR12D1 shows higher tumor expression in CHOL. The CHOL box plot shows higher OR12D1 RNA expression in tumor versus normal tissue (log2 FC = +1.052, t-test p = .038).
This table shows molecular features associated with OR12D1 in patient tissues and cancer cell lines. In patient samples, OR12D1 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR12D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
